- Trials with a EudraCT protocol (270)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (25)
270 result(s) found for: Amylase.
Displaying page 4 of 14.
EudraCT Number: 2006-006615-80 | Sponsor Protocol Number: matisse1 | Start Date*: 2007-02-23 |
Sponsor Name:Royal Marsden Nhs Foundation Trust | ||
Full Title: A Pilot Study in Metastatic Advanced Thyroid Cancer Evaluating the Safety and Efficacy of Sorafenib | ||
Medical condition: Patients with localled advanced or metastatic thyroid cancer . histological sub-types will include differentiated and medullary thyroid cancer. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2015-002526-39 | Sponsor Protocol Number: 20010133 | Start Date*: 2015-07-02 |
Sponsor Name:Swedish Orphan Biovitrum AB (publ) | ||
Full Title: A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Pediatric Subjects with Acute Leukemias Undergoing Myeloblative Therapy and Allogeneic Hematopoieti... | ||
Medical condition: Oral Mucositis | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2007-001781-32 | Sponsor Protocol Number: MAPS | Start Date*: 2007-06-14 | |||||||||||
Sponsor Name:GISCAD | |||||||||||||
Full Title: A randomized phase II study of gemcitabine/cisplatin with or without sorafenib to evaluate the efficacy and safety in patients with locally advanced or metastatic pancreatic cancer. MAPS trial | |||||||||||||
Medical condition: Subjects enrolled in this study must have histologically confirmed locally advanced or metastatic pancreatic adenocarcinoma. They must not have been received a first-line chemotherapy. Presence of ... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-017871-13 | Sponsor Protocol Number: ME GD 203 | Start Date*: 2010-10-05 | |||||||||||
Sponsor Name:New Medical Enzymes AG | |||||||||||||
Full Title: A multicenter phase II study to evaluate safety and efficacy of glutadon once weekly (GDO) in patients with metastatic colorectal cancer resistant or intolerable to approved chemo- and molecular-ta... | |||||||||||||
Medical condition: Adult patients with unresectable or metastatic colorectal cancer showing progression of disease on at least one fluoropyrimidine derivative, oxaliplatin, irinotecan and EGFR-antibodies (cetuximab o... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003137-32 | Sponsor Protocol Number: ITMO 002 | Start Date*: 2006-09-26 | |||||||||||
Sponsor Name:I.T.M.O. - ITALIAN TRIALS IN MEDICAL ONCOLOGY | |||||||||||||
Full Title: A randomized, open label, multicenter phase II study of first line therapy with Sorafenib in association with Interleukin 2 versus Sorafenib alone in patients with unresectable and/or metastatic re... | |||||||||||||
Medical condition: ADVANCED RENAL CELL CANCER | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-005138-39 | Sponsor Protocol Number: GS-US-311-1089 | Start Date*: 2014-05-16 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects who are Virologically Suppressed on Regimens containing FTC/TDF | |||||||||||||
Medical condition: Human Immunodeficiency Virus (HIV-1) Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000501-22 | Sponsor Protocol Number: SPON1189-13 | Start Date*: 2013-10-30 | |||||||||||
Sponsor Name:Cardiff Univeristy | |||||||||||||
Full Title: A national cancer research institute acute myeloid leukaemia working group pilot trial under the auspices of the cardiff experimental cancer medicine centre to establish the feasibility of combinin... | |||||||||||||
Medical condition: Acute Myeloid Leukaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004587-23 | Sponsor Protocol Number: UZL/MBC SUBE0501 | Start Date*: 2005-12-23 |
Sponsor Name:UZ Leuven | ||
Full Title: A belgian multicenter phase II randomized trial in her2 negative metastatic breast cancer evaluating consolidation antiangiogenic therapy with SU11248 after response to taxane chemotherapy induction | ||
Medical condition: Patients must meet all of the following inclusion criteria in order to be eligible for participation in this study: • Patients with metastatic breast cancer, histologically proven • Patients receiv... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-003343-11 | Sponsor Protocol Number: GLP1ALCOHOL | Start Date*: 2017-04-12 | |||||||||||
Sponsor Name:Psychiatric Centre Copenhagen | |||||||||||||
Full Title: Does Glucagon-like Peptide 1 (GLP-1) receptor stimulation reduce alcohol intake in patients with alcohol dependence? | |||||||||||||
Medical condition: Alcohol dependence | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003245-29 | Sponsor Protocol Number: SA652013 | Start Date*: 2016-12-19 |
Sponsor Name:Amsterdam AMC, locatie AMC | ||
Full Title: Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after Roux-en-Y gastric bypass and Sleeve Gastrectomy | ||
Medical condition: Prevention of symptomatic gallstone disease | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-002744-74 | Sponsor Protocol Number: F3-IROzono-COVID-19 | Start Date*: 2022-06-23 | |||||||||||
Sponsor Name:Sociedad Española de Ozonoterapia - SEOT [...] | |||||||||||||
Full Title: Effect of rectal ozone therapy on the clinical progress of hospitalized patients with mild-moderate covid19 infection: A triple- blind, randomized controlled trial. | |||||||||||||
Medical condition: COVID-19 infection requiring hospitalization | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000788-26 | Sponsor Protocol Number: WATERFALL | Start Date*: 2019-06-10 | |||||||||||
Sponsor Name:Enrique de Madaria | |||||||||||||
Full Title: Effect of early weight-based aggressive versus non-aggressive goal-directed fluid resuscitation in the early phase of acute pancreatitis: an open-label multicenter randomized-controlled trial | |||||||||||||
Medical condition: Acute pancreatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004231-12 | Sponsor Protocol Number: NL20151001 | Start Date*: 2016-08-08 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Early identification of patients who benefit from palbociclib in addition to letrozole | ||
Medical condition: estrogen receptor positive metastatic breast cancer patients eligible for palbociclib plus letrozole treatment | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2023-000010-18 | Sponsor Protocol Number: WATERLAND | Start Date*: 2023-03-23 | |||||||||||
Sponsor Name:Enrique de Madaria | |||||||||||||
Full Title: Normal saline versus lactated Ringer’s solution for acute pancreatitis resuscitation, an open-label multicenter randomized controlled trial: the WATERLAND trial | |||||||||||||
Medical condition: Acute pancreatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000644-94 | Sponsor Protocol Number: VA_2012/01 | Start Date*: 2012-06-28 | |||||||||||
Sponsor Name:Centre Val d’Aurelle - Paul Lamarque | |||||||||||||
Full Title: A randomized phase II trial assessing Sorafenib (Nexavar®) in combination with irinotecan in metastatic colorectal cancer patients with KRAS mutated tumours after failure of all active drugs known ... | |||||||||||||
Medical condition: metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002338-31 | Sponsor Protocol Number: 47 | Start Date*: 2008-08-29 | |||||||||||
Sponsor Name:Hannover Medical School | |||||||||||||
Full Title: Prospektive randomisierte Phase II Studie zur Behandlung von Patienten mit fortgeschrittenem hormonrefraktären Prostatakarzinom mittels LHRH-Analoga und Somatostatin-Analoga unter Berücksichtigung ... | |||||||||||||
Medical condition: Patients with hormone - independent non metastatic prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004674-34 | Sponsor Protocol Number: P16/23 | Start Date*: 2018-09-25 |
Sponsor Name:CENTRE HOSPITALIER DE VERSAILLES | ||
Full Title: OPEN LABEL PHASE 2 STUDY ON THE EFFICACY AND TOLERANCE OF A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS | ||
Medical condition: CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2020-002313-18 | Sponsor Protocol Number: PAMORA-AP_2020 | Start Date*: 2020-12-22 | |||||||||||
Sponsor Name:Mech-Sense, Aalborg University Hospital | |||||||||||||
Full Title: The effects of opioid receptor antagonism on acute pancreatitis: An investigator initiated, randomized, placebo-controlled, double-blind clinical trial | |||||||||||||
Medical condition: Acute pancreatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000582-36 | Sponsor Protocol Number: BREAKPOINT | Start Date*: 2018-05-17 | |||||||||||
Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI" | |||||||||||||
Full Title: A phase 2 open label study of caBozantinib in patients with advanced or unresectable Renal cEll cArcinoma pretreated with one immunochecKPOint INhibiTor (anti PD1/PDL1) | |||||||||||||
Medical condition: Patients with metastatic clear cell renal cell carcinoma pretreated with immunocheckpoints inhibitors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002655-26 | Sponsor Protocol Number: BCX4161-301 | Start Date*: 2015-02-09 | |||||||||||
Sponsor Name:BioCryst Pharmaceuticals Inc | |||||||||||||
Full Title: OPuS-2 A multicentre, randomised, double blind, placebo controlled, parallel group study to evaluate the efficacy and safety of two dose levels of BCX4161 for 12 weeks as an oral prophylaxis treatm... | |||||||||||||
Medical condition: Hereditary Angioedema | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) HU (Completed) BE (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
